RU2019134045A - Терапевтический агент для лечения рака крови - Google Patents
Терапевтический агент для лечения рака крови Download PDFInfo
- Publication number
- RU2019134045A RU2019134045A RU2019134045A RU2019134045A RU2019134045A RU 2019134045 A RU2019134045 A RU 2019134045A RU 2019134045 A RU2019134045 A RU 2019134045A RU 2019134045 A RU2019134045 A RU 2019134045A RU 2019134045 A RU2019134045 A RU 2019134045A
- Authority
- RU
- Russia
- Prior art keywords
- nucleic acid
- modified nucleic
- guanosine
- oligonucleotide containing
- blood cancer
- Prior art date
Links
- 201000005787 hematologic cancer Diseases 0.000 title claims 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 title claims 6
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 102000039446 nucleic acids Human genes 0.000 claims 16
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 13
- 108091034117 Oligonucleotide Proteins 0.000 claims 11
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 6
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 5
- 229940029575 guanosine Drugs 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 125000004437 phosphorous atom Chemical group 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 229940113082 thymine Drugs 0.000 claims 2
- WRADPCFZZWXOTI-BMRADRMJSA-N (9E)-10-nitrooctadecenoic acid Chemical compound CCCCCCCC\C([N+]([O-])=O)=C/CCCCCCCC(O)=O WRADPCFZZWXOTI-BMRADRMJSA-N 0.000 claims 1
- OVYNGSFVYRPRCG-UHFFFAOYSA-N 2'-O-Methylguanosine Natural products COC1C(O)C(CO)OC1N1C(NC(N)=NC2=O)=C2N=C1 OVYNGSFVYRPRCG-UHFFFAOYSA-N 0.000 claims 1
- OVYNGSFVYRPRCG-KQYNXXCUSA-N 2'-O-methylguanosine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=C(N)NC2=O)=C2N=C1 OVYNGSFVYRPRCG-KQYNXXCUSA-N 0.000 claims 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 claims 1
- BGTXMQUSDNMLDW-AEHJODJJSA-N 2-amino-9-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)F BGTXMQUSDNMLDW-AEHJODJJSA-N 0.000 claims 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 108091081406 G-quadruplex Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 102000055027 Protein Methyltransferases Human genes 0.000 claims 1
- 108700040121 Protein Methyltransferases Proteins 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/09—Pyrimidine radicals with arabinosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (29)
1. Олигонуклеотид, содержащий модифицированную нуклеиновую кислоту, включающий соединение, представленное следующей формулой 1, с образованием G-квадруплекса:
Формула 1
где R1 представляет атом водорода или фосфора фосфатной группы другой нуклеиновой кислоты, и
R2 представляет атом водорода или фосфора фосфатной группы другой нуклеиновой кислоты.
2. Олигонуклеотид, содержащий модифицированную нуклеиновую кислоту, по п. 1, где соединение представлено следующей формулой 2:
Формула 2
3. Олигонуклеотид, содержащий модифицированную нуклеиновую кислоту, по п. 2, где олигонуклеотид, содержащий модифицированную нуклеиновую кислоту, представлен следующей последовательностью:
GaTbNc
где G представляет гуанозин или производное гуанозина;
T представляет тимин или производное тимина;
N представляет 1-β-D-арабинофуранозилцитозин в качестве модифицированной нуклеиновой кислоты;
G, T и N случайным образом распределены посредством пермутации; и
a представляет целое число, выбранное из 1-30, b представляет целое число, выбранное из 0-30, и c представляет целое число, выбранное из 1-30, при условии, что общее число a, b и c не превышает 60.
4. Олигонуклеотид, содержащий модифицированную нуклеиновую кислоту по п. 3, где олигонуклеотид, содержащий модифицированную нуклеиновую кислоту, представлен следующей последовательностью:
последовательность 1) GGTGGTGGTTNTGGTGGTGG;
последовательность 2) GGTGGTGGTNNTGGTGGTGG;
последовательность 3) NGGTGGTGGTTGTGGTGGTGG; или
последовательность 4) NNGGTGGTGGTTGTGGTGGTGG.
где G представляет гуанозин или производное гуанозина;
T представляет тимин или производное тимина; и
N представляет 1-β-D-арабинофуранозилцитозин в качестве модифицированной нуклеиновой кислоты.
5. Олигонуклеотид, содержащий модифицированную нуклеиновую кислоту по п. 3, где гуанозин или производное гуанозина включает одно или более, выбранных из 2-дезоксигуанозина, гуанозина, 2'-O-метилгуанозина, 2'-фторгуанозина, LNA (закрытой нуклеиновой кислоты)гуанозина, D-дезоксигуанозина и D-гуанозина.
6. Композиция для профилактики, облегчения течения или лечения рака крови, содержащая олигонуклеотид, содержащий модифицированную нуклеиновую кислоту, по любому из пп. 1-5 или его фармацевтически приемлемую соль в качестве активного ингредиента.
7. Композиция для профилактики, облегчения течения или лечения рака крови по п. 6, где рак крови включает по меньшей мере одно из неходжкинской лимфомы, ходжкинской лимфомы, множественной миеломы, лейкоза, лимфомы, миелодиспластического синдрома (MDS), острого лимфобластного лейкоза, острого миелоидного лейкоза, хронического лимфоцитарного лейкоза, хронического миелоидного лейкоза и солитарной миеломы.
8. Композиция для профилактики, облегчения течения или лечения рака крови, резистентного по меньшей мере к одному из цитарабина, децитабина и азацитидина, в качестве ингибиторов ДНК-синтетазы или ДНК-метилтрансферазы, содержащая олигонуклеотид, содержащий модифицированную нуклеиновую кислоту, по любому из пп. 1-5 или его фармацевтически приемлемую соль в качестве активного ингредиента.
9. Композиция для профилактики, облегчения течения или лечения острого миелоидного лейкоза, имеющая высокие эффекты индукции апоптоза на мононуклеарных клетках костного мозга, полученных от пациентов с рецидивирующим/трудно поддающимся лечению острым миелоидным лейкозом, содержая олигонуклеотид, содержащий модифицированную нуклеиновую кислоту, по любому из пп. 1-5 или его фармацевтически приемлемую соль в качестве активного ингредиента.
10. Композиция для облегчения течения или лечения рака крови, имеющая более высокие эффекты индукции апоптоза в раковых клетках, чем в нормальных клетках, содержащая олигонуклеотид, содержащий модифицированную нуклеиновую кислоту, по любому из пп. 1-5 или его фармацевтически приемлемую соль в качестве активного ингредиента.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0164409 | 2017-12-01 | ||
| KR20170164409 | 2017-12-01 | ||
| KR1020180150255A KR20190065139A (ko) | 2017-12-01 | 2018-11-29 | 혈액암 치료제 |
| KR10-2018-0150255 | 2018-11-29 | ||
| PCT/KR2018/015054 WO2019108004A2 (en) | 2017-12-01 | 2018-11-30 | Therapeutic agent for blood cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019134045A true RU2019134045A (ru) | 2021-04-26 |
| RU2019134045A3 RU2019134045A3 (ru) | 2021-04-26 |
| RU2751233C2 RU2751233C2 (ru) | 2021-07-12 |
Family
ID=66846839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019134045A RU2751233C2 (ru) | 2017-12-01 | 2018-11-30 | Терапевтический агент для лечения рака крови |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20230192752A1 (ru) |
| EP (1) | EP3610020A4 (ru) |
| JP (1) | JP7027448B2 (ru) |
| KR (3) | KR20190065139A (ru) |
| CN (1) | CN110573620B (ru) |
| AU (1) | AU2018375468B2 (ru) |
| CA (1) | CA3059363C (ru) |
| IL (1) | IL270140B (ru) |
| MX (1) | MX2019012318A (ru) |
| PH (1) | PH12019502290A1 (ru) |
| RU (1) | RU2751233C2 (ru) |
| WO (1) | WO2019108004A2 (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190065139A (ko) * | 2017-12-01 | 2019-06-11 | 압타바이오 주식회사 | 혈액암 치료제 |
| CN113727719A (zh) * | 2020-07-17 | 2021-11-30 | 德尔塔菲制药股份有限公司 | 血癌的新型治疗方法及新型治疗剂 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567604A (en) | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
| CZ227199A3 (cs) | 1996-12-27 | 1999-12-15 | Icn, Pharmaceuticals, Inc. | Aptamer |
| ATE375358T1 (de) | 1999-04-08 | 2007-10-15 | Antisoma Res Ltd | Antiproliferative aktivität von g-reichen oligonukleotiden und verfahren um sie zur bindung an nukleotin zu verwenden |
| TW200637870A (en) * | 2005-01-31 | 2006-11-01 | Taiho Pharmaceutical Co Ltd | Novel pyrimidine nucleoside compound and salt thereof |
| CA2625035A1 (en) | 2005-10-06 | 2007-04-19 | University Of Delaware | G-rich polynucleotides for the treatment of huntington's disease |
| KR100998365B1 (ko) | 2009-06-29 | 2010-12-06 | 압타바이오 주식회사 | 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체 |
| US20160281090A1 (en) * | 2013-11-06 | 2016-09-29 | Advanced Cancer Therapeutics, Llc | Modified dna quadruplex-forming oligonucleotides and methods of use |
| KR20170005492A (ko) * | 2014-05-28 | 2017-01-13 | 아이데닉스 파마슈티칼스 엘엘씨 | 암의 치료를 위한 뉴클레오시드 유도체 |
| KR20190065139A (ko) * | 2017-12-01 | 2019-06-11 | 압타바이오 주식회사 | 혈액암 치료제 |
-
2018
- 2018-11-29 KR KR1020180150255A patent/KR20190065139A/ko not_active Ceased
- 2018-11-30 CN CN201880027374.9A patent/CN110573620B/zh active Active
- 2018-11-30 RU RU2019134045A patent/RU2751233C2/ru active
- 2018-11-30 AU AU2018375468A patent/AU2018375468B2/en active Active
- 2018-11-30 EP EP18883330.5A patent/EP3610020A4/en active Pending
- 2018-11-30 CA CA3059363A patent/CA3059363C/en active Active
- 2018-11-30 US US16/609,367 patent/US20230192752A1/en not_active Abandoned
- 2018-11-30 MX MX2019012318A patent/MX2019012318A/es unknown
- 2018-11-30 WO PCT/KR2018/015054 patent/WO2019108004A2/en not_active Ceased
- 2018-11-30 JP JP2019558534A patent/JP7027448B2/ja active Active
-
2019
- 2019-10-03 PH PH12019502290A patent/PH12019502290A1/en unknown
- 2019-10-24 IL IL270140A patent/IL270140B/en unknown
-
2020
- 2020-03-20 KR KR1020200034511A patent/KR102258152B1/ko active Active
- 2020-03-20 KR KR1020200034510A patent/KR102097519B1/ko active Active
-
2025
- 2025-06-17 US US19/240,678 patent/US20250304612A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12019502290A1 (en) | 2020-07-06 |
| AU2018375468A1 (en) | 2019-11-07 |
| CN110573620A (zh) | 2019-12-13 |
| US20250304612A1 (en) | 2025-10-02 |
| EP3610020A2 (en) | 2020-02-19 |
| RU2751233C2 (ru) | 2021-07-12 |
| IL270140B (en) | 2021-12-01 |
| US20230192752A1 (en) | 2023-06-22 |
| KR20200033835A (ko) | 2020-03-30 |
| JP7027448B2 (ja) | 2022-03-01 |
| EP3610020A4 (en) | 2021-01-27 |
| KR102097519B1 (ko) | 2020-04-06 |
| MX2019012318A (es) | 2020-01-27 |
| WO2019108004A3 (en) | 2019-07-18 |
| KR20190065139A (ko) | 2019-06-11 |
| KR102258152B1 (ko) | 2021-05-31 |
| RU2019134045A3 (ru) | 2021-04-26 |
| BR112019022459A2 (pt) | 2020-06-16 |
| CA3059363A1 (en) | 2019-06-06 |
| JP2020517716A (ja) | 2020-06-18 |
| KR20200033836A (ko) | 2020-03-30 |
| AU2018375468B2 (en) | 2021-04-08 |
| CN110573620B (zh) | 2024-04-23 |
| CA3059363C (en) | 2023-03-14 |
| WO2019108004A2 (en) | 2019-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qin et al. | Effect of cytarabine and decitabine in combination in human leukemic cell lines | |
| Stomper et al. | Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies | |
| Hackanson et al. | Decitabine | |
| Gore et al. | Decitabine | |
| RU2016146819A (ru) | Композиции и способы модулирования экспрессии рецептора гормона роста | |
| Thottassery et al. | Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4′-thio-2′-deoxycytidine and 5-aza-4′-thio-2′-deoxycytidine | |
| PH12022553530A1 (en) | 1'-cyano nucleoside analogs and uses thereof | |
| EA201500748A1 (ru) | Ингибирующие олигонуклеотиды и их применение в терапии | |
| HRP20241138T1 (hr) | Oligonukleotidi za induciranje ekspresije očinskog ube3a | |
| Pui et al. | Clofarabine | |
| RU2014117018A (ru) | Аптамер против ngf и его применение | |
| RU2016146817A (ru) | Композиции и способы модулирования экспрессии ангиопоэтин-подобного белка 3 | |
| RU2019130513A (ru) | Антисмысловые нуклеиновые кислоты | |
| AR082067A2 (es) | Analogos de nucleosidos fluorados modificados | |
| IL186104A (en) | Phosphoramidate History of Nucleoside Compounds | |
| RU2015111672A (ru) | Модулирование экспрессии рецептора андрогенов | |
| Da Costa et al. | DNA methylation–targeted drugs | |
| JP2018522038A5 (ru) | ||
| RU2019134045A (ru) | Терапевтический агент для лечения рака крови | |
| AR112702A1 (es) | Derivados de nucleósidos sustituidos con 4-fluoro-2-metilo como inhibidores de la replicación de hcv arn | |
| JP2011515357A5 (ru) | ||
| Müller et al. | 5-Azacytidine/5-Azacitidine | |
| Ghez et al. | Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis | |
| WO2007067364A3 (en) | Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs | |
| JP2017506259A5 (ru) |